See the raw experimental evidence behind an author's publications and reproducibility signals.
Press Enter ↵ to solve
Fuel Your Discoveries
"The first principle is that you must not fool yourself — and you are the easiest person to fool."
- Richard Feynman
Quick Explanation
Copied
Author Review (evidence-limited)
I can only assess what’s explicitly provided: a narrative review by Mee-Hyun Lee et al. on CRISPR/Cas9 in cancer biology (npj Precision Oncology, 2019) .
Long Explanation
Author Review: Mee-Hyun Lee
Epistemic status: I only evaluate what is explicitly provided in the prompt (one cited narrative review and the extracted metadata/stats tied to it). I do not have reliable OpenAlex author records here (OpenAlex request timed out), so citation metrics are not asserted.
What I can assess from the provided evidence
Primary item provided
Review article: “CRISPR/Cas9 – An evolving biological tool kit for cancer biology and oncology” (npj Precision Oncology, 2019)
The prompt states this item is a narrative literature review (no new human/animal experimental data generated by the authors) .
Visual evidence summaries (from the provided extracted numbers)
Values shown come from the prompt’s extracted statistics and are attributed to the provided review context .
These fractions are taken directly from the extracted prompt statistics associated with the same review .
Trial counts are those included in the prompt’s extracted stats from the review .
Scientific strength: what the evidence suggests
1) Scope and technical coverage
The provided item describes a broad set of CRISPR/Cas9 capabilities relevant to cancer biology—genome editing, transcriptional regulation via derivatives (e.g., dCas9-based approaches), and scalable screening/library strategies—along with translational considerations .
Uncertainty/limitation: because this is a narrative review, the strength of the technical claims depends on the underlying cited primary literature rather than direct experimental output from the author(s). The prompt also indicates this is not new subject data .
2) Evidence quality risks inherent to narrative reviews
The prompt’s metadata explicitly flags biases typical of narrative reviews: variability in study designs and potential publication bias, plus the translational gap between preclinical models and human therapy .
Critical note: The review can still be valuable for synthesis, but the author’s “scientific strength” (in this narrow sense) is best judged by how faithfully they represent uncertainty, heterogeneity (cell line vs organoid vs in vivo), and safety metrics (off-target and delivery), which are emphasized in the provided abstract-like summary .
3) Translational realism vs mechanistic optimism
The provided description indicates the review presents translational potential (including clinical trials) while also naming persistent barriers: delivery, off-target edits, safety, and ethics .
What could change this assessment: If future evidence (or other works by the author) shows more rigorous quantitative synthesis (e.g., systematic review/meta-analysis) or primary experimental contributions demonstrating reproducibility/safety, my “scientific strength” score should increase; conversely, selective emphasis on positive findings would decrease it.
Data completeness & what’s missing
Author identity metrics: OpenAlex author metadata was not retrievable (timeout), so I cannot responsibly report the author’s citation counts, h-index, or publication list from that source.
Only one paper item provided: Without additional Mee-Hyun Lee publications, co-authorship context, or direct extracts beyond the single review, I can’t evaluate trends in the author’s scientific direction (e.g., whether they contribute primary mechanistic studies vs primarily synthesis).
Reproducibility: Narrative reviews are not meant to be “reproducible” in the same way as experiments; instead, their claims are only as strong as the cited primary works and how comprehensively they cover counterevidence.
Recommended next BGPT actions
Scope boundary: Because no additional Mee-Hyun Lee works were provided here, this evaluation is specifically about the provided narrative review item.
This will attempt an iterative, evidence-grounded deep dive from available full-text sources.
Feedback:
Updated: March 28, 2026
BGPT Author Review
Scientific Quality
50%
Based only on the provided single narrative review item, the scientific quality appears solid in breadth and topical relevance to CRISPR/Cas9 in cancer, with appropriate emphasis on known translational barriers (delivery, off-target, safety). However, narrative reviews are limited in rigor versus primary experiments and may be vulnerable to coverage/publication bias; I also cannot assess the author’s broader track record because only one item was provided and author-level citation metrics were unavailable.
Communication Quality
60%
The provided abstract-style summary suggests clear technical structuring (toolkit variants, screening, models, clinical translation, and challenges). But I can’t judge the actual writing quality (clarity, figures, argumentative balance) without more text from the review and without additional works.
Author Novelty
40%
A CRISPR/Cas9 cancer synthesis review in 2019 is likely more consolidative than novel-generative; novelty can’t be confirmed without additional author publications or excerpts showing unique methods/data synthesis beyond summarizing existing work.
Scientific Rigor
50%
Rigor is constrained because the work is characterized as a narrative review with no new subject experiments. The prompt’s metadata acknowledges typical narrative-review limitations, and I cannot verify the completeness of counterevidence or whether claims are systematically derived from high-quality primary studies.
Would extract the review’s provided CRISPR cancer statistics, compile them into structured arrays, and generate publication/subtype/topic visual dashboards to compare emphases and clinical trial trends.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
“Off-target effects are the main driver of poor reproducibility across all CRISPR cancer phenotypes.” This is less favored because delivery modality, cellular stress, and model heterogeneity can plausibly dominate; off-target is important but likely not uniformly primary in every context.
“Clinical failure of CRISPR cancer therapies is mostly due to lack of target discovery rather than delivery/safety constraints.” This is less favored because the provided summary emphasizes delivery/off-target/safety/ethics as key challenges, and trial counts alone don’t establish target-discovery insufficiency.
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
BGPT Author Review
Analysis Wizard
Hypothesis Graveyard
Discussion
Fuel Your Discoveries
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
